5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene | 7140-66-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 环七噻吩
• 英文名称: 5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene
• 英文别名: 5,6,7,8-Tetrahydro-4H-cyclohepta[b]thiophen
• CAS: 7140-66-1
• 化学式: C₉H₁₂S
• 分子量: 152.26
• InChiKey: PDDJLLYFHMMVJG-UHFFFAOYSA-N

物化性质

• 沸点：
  237.9±9.0 °C(Predicted)
• 密度：
  1.061±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene 在 二硫化碳 、 氢氧化钾 、 三氯化铝 、 羟胺 、 一水合肼 、 二乙二醇 作用下， 生成 1-(2-ethyl-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophen-3-yl)-ethanone oxime
  参考文献：
  名称：

  Cagniant; Cagniant, Bulletin de la Societe Chimique de France, 1955, p. 680,684

  摘要：

  DOI：
• 作为产物：
  描述：

  5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophen-4-one 在 氢氧化钾 、 一水合肼 、 二乙二醇 作用下， 生成 5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene
  参考文献：
  名称：

  Cagniant; Cagniant, Bulletin de la Societe Chimique de France, 1955, p. 680,684

  摘要：

  DOI：

文献信息

• HETEROCYCLIC COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF
  申请人：SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

  公开号：US20170158680A1

  公开（公告）日：2017-06-08

  The present invention provides a heterocyclic compound represented by the formula (I), its stereoisomers, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and their use in preparing a medicament for the prevention and/or treatment of central nervous system disease.

  本发明提供了一种由公式（I）表示的杂环化合物，其立体异构体，或其药用可接受的盐，其药物组合物，以及它们用于制备预防或治疗中枢神经系统疾病的药物。
• Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1388342A1

  公开（公告）日：2004-02-11

  The present invention relates to acylated, heteroaryl-condensed cycloalkenylamines of the formula I, in which A, R1, R2, R3, R4, R5 and n have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds which are useful in the treatment of various disease states including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency. They upregulate the expression of the enzyme endothelial nitric oxide (NO) synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及公式I的酰化的异杂环缩合环烯基胺，其中A，R1，R2，R3，R4，R5和n具有声明中指定的含义。公式I的化合物是有价值的药理活性化合物，可用于治疗各种疾病状态，包括心血管疾病，如动脉粥样硬化，血栓形成，冠状动脉疾病，高血压和心脏衰竭。它们升调内皮一氧化氮（NO）合酶的表达，并可应用于需要增加该酶的表达或增加NO水平或恢复降低的NO水平的情况。本发明还涉及公式I化合物的制备方法，它们的使用，特别是作为药物中的活性成分，以及包含它们的制药制剂。
• Substituted Azepine Derivatives As Serotonin Receptor Modulators
  申请人：Bennani Youssef L.

  公开号：US20100190772A1

  公开（公告）日：2010-07-29

  The present invention generally relates to compounds and pharmaceutical compositions containing the compounds. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).

  本发明通常涉及化合物和含有这些化合物的药物组合物。更具体地说，本发明的化合物是六氢吲哚并环己氮化吲哚和八氢吲哚并环己氮化吲哚化合物。这些化合物是血清素受体(5-HT)配体，可用于治疗希望调节血清素受体(5-HT)活性的疾病、障碍和病况(例如焦虑、抑郁和肥胖症)。
• Substituted hydroxamic acids and uses thereof
  申请人：Blackburn Christopher

  公开号：US20110046157A1

  公开（公告）日：2011-02-24

  This invention provides compounds of formula (I): wherein R 1 , R 2 , G, n, p and q have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.

  本发明提供了式(I)的化合物： 其中R1、R2、G、n、p和q的值如说明书所述，可用作HDAC6的抑制剂。该发明还提供了包括该发明中的化合物的制药组合物以及使用该组合物治疗增生性、炎症性、感染性、神经系统或心血管疾病或紊乱的方法。
• POTASSIUM CHANNEL MODULATORS
  申请人：Scanio Marc J.

  公开号：US20100305109A1

  公开（公告）日：2010-12-02

  Disclosed herein are KCNQ potassium channels modulators of formula (I) wherein ring G 1 , X, R 1 , and R 2 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

  本文披露了公式（I）中的KCNQ钾通道调节剂，其中环G1、X、R1和R2如规范所定义。还描述了包含这些化合物的组合物；以及使用这些化合物和组合物治疗疾病和疾病的方法。